Details for Patent: 10,981,952
✉ Email this page to a colleague
Which drugs does patent 10,981,952 protect, and when does it expire?
Patent 10,981,952 protects BYLVAY and is included in one NDA.
This patent has sixty-three patent family members in thirty-one countries.
Summary for Patent: 10,981,952
Title: | IBAT inhibitors for the treatment of liver diseases |
Abstract: | The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions. |
Inventor(s): | Gillberg; Per-Goran (Molndal, SE), Graffner; Hans (Helsingborg, SE), Starke; Ingemar (Gothenburg, SE) |
Assignee: | Albireo AB (Goteborg, SE) |
Application Number: | 16/737,742 |
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,981,952
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) | ⤷ Try a Trial | ||||
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) | ⤷ Try a Trial | ||||
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS) | ⤷ Try a Trial | ||||
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS) | ⤷ Try a Trial | ||||
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-003 | Jul 20, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,981,952
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Sweden | 1051165-7 | Nov 8, 2010 |
International Family Members for US Patent 10,981,952
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2011326871 | ⤷ Try a Trial | |||
Brazil | 112013010157 | ⤷ Try a Trial | |||
Canada | 2815749 | ⤷ Try a Trial | |||
China | 103260625 | ⤷ Try a Trial | |||
China | 105288580 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |